Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

23.23 -0.24 (-1.02%)
Streaming Delayed Price Updated: 12:49 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Analyst Ratings for Rocket Pharmaceuticals
Via Benzinga
Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) Near the Top of Equities by Percentage Gain on 9/13
Via Investor Brand Network
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Stock Sees Improved Price Strength
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets. 
Via The Motley Fool
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully
Its near-term risks are subtle but bigger than their flying stock price might indicate. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, under followed and emerging stocks. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. 
Via Benzinga
Dow Turns Lower; KULR Technology Group Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling 100 points on Wednesday. The Dow traded down 0.29% to 34,545.66 while the NASDAQ rose 0.22% to 13,803.43. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
With Rocket Pharmaceuticals reaching a Phase II agreement with the FDA, RCKT stock soared, though some concerns linger. 
Via InvestorPlace
Exposures Product Safety
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Gains 50 Points; US Crude Oil Inventories Rise
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 50 points on Wednesday. The Dow traded up 0.16% to 34,701.06 while the NASDAQ rose 0.44% to 13,834.85. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy. 
Via The Motley Fool
What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today?
On Tuesday, Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501  
Via Benzinga
Exposures Product Safety
Moderna, REV Group, Rocket Pharmaceuticals And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.